These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 34428777)

  • 1. Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.
    Annavajhala MK; Mohri H; Wang P; Nair M; Zucker JE; Sheng Z; Gomez-Simmonds A; Kelley AL; Tagliavia M; Huang Y; Bedford T; Ho DD; Uhlemann AC
    Nature; 2021 Sep; 597(7878):703-708. PubMed ID: 34428777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York.
    Annavajhala MK; Mohri H; Wang P; Nair M; Zucker JE; Sheng Z; Gomez-Simmonds A; Kelley AL; Tagliavia M; Huang Y; Bedford T; Ho DD; Uhlemann AC
    medRxiv; 2021 Aug; ():. PubMed ID: 33655278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
    Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
    mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
    Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil.
    Naveca FG; Nascimento V; Souza V; Corado AL; Nascimento F; Silva G; Mejía MC; Brandão MJ; Costa Á; Duarte D; Pessoa K; Jesus M; Gonçalves L; Fernandes C; Mattos T; Abdalla L; Santos JH; Martins A; Chui FM; Val FF; de Melo GC; Xavier MS; Sampaio VS; Mourão MP; Lacerda MV; Batista ÉLR; Magalhães ALÁ; Dábilla N; Pereira LCG; Vinhal F; Miyajima F; Dias FBS; Dos Santos ER; Coêlho D; Ferraz M; Lins R; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Resende PC; Bello G;
    Microbiol Spectr; 2022 Feb; 10(1):e0236621. PubMed ID: 35196783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York.
    West AP; Wertheim JO; Wang JC; Vasylyeva TI; Havens JL; Chowdhury MA; Gonzalez E; Fang CE; Di Lonardo SS; Hughes S; Rakeman JL; Lee HH; Barnes CO; Gnanapragasam PNP; Yang Z; Gaebler C; Caskey M; Nussenzweig MC; Keeffe JR; Bjorkman PJ
    Nat Commun; 2021 Aug; 12(1):4886. PubMed ID: 34373458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
    Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ
    PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey.
    Mathema B; Chen L; Wang P; Cunningham MH; Mediavilla JR; Chow KF; Luo Y; Zhao Y; Composto K; Zuckerman J; Zody MC; Wilson N; Lee A; Oschwald DM; Liu L; Iketani S; Germer S; Fennessey S; Wang M; Kramer Y; Toole P; Maniatis T; Ho DD; Perlin DS; Kreiswirth BN
    mBio; 2022 Oct; 13(5):e0214122. PubMed ID: 35997285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions.
    Dudas G; Hong SL; Potter BI; Calvignac-Spencer S; Niatou-Singa FS; Tombolomako TB; Fuh-Neba T; Vickos U; Ulrich M; Leendertz FH; Khan K; Huber C; Watts A; Olendraitė I; Snijder J; Wijnant KN; Bonvin AMJJ; Martres P; Behillil S; Ayouba A; Maidadi MF; Djomsi DM; Godwe C; Butel C; Šimaitis A; Gabrielaitė M; Katėnaitė M; Norvilas R; Raugaitė L; Koyaweda GW; Kandou JK; Jonikas R; Nasvytienė I; Žemeckienė Ž; Gečys D; Tamušauskaitė K; Norkienė M; Vasiliūnaitė E; Žiogienė D; Timinskas A; Šukys M; Šarauskas M; Alzbutas G; Aziza AA; Lusamaki EK; Cigolo JM; Mawete FM; Lofiko EL; Kingebeni PM; Tamfum JM; Belizaire MRD; Essomba RG; Assoumou MCO; Mboringong AB; Dieng AB; Juozapaitė D; Hosch S; Obama J; Ayekaba MO; Naumovas D; Pautienius A; Rafaï CD; Vitkauskienė A; Ugenskienė R; Gedvilaitė A; Čereškevičius D; Lesauskaitė V; Žemaitis L; Griškevičius L; Baele G
    Nat Commun; 2021 Oct; 12(1):5769. PubMed ID: 34599175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of a SARS-CoV-2 variant of concern in South Africa.
    Tegally H; Wilkinson E; Giovanetti M; Iranzadeh A; Fonseca V; Giandhari J; Doolabh D; Pillay S; San EJ; Msomi N; Mlisana K; von Gottberg A; Walaza S; Allam M; Ismail A; Mohale T; Glass AJ; Engelbrecht S; Van Zyl G; Preiser W; Petruccione F; Sigal A; Hardie D; Marais G; Hsiao NY; Korsman S; Davies MA; Tyers L; Mudau I; York D; Maslo C; Goedhals D; Abrahams S; Laguda-Akingba O; Alisoltani-Dehkordi A; Godzik A; Wibmer CK; Sewell BT; Lourenço J; Alcantara LCJ; Kosakovsky Pond SL; Weaver S; Martin D; Lessells RJ; Bhiman JN; Williamson C; de Oliveira T
    Nature; 2021 Apr; 592(7854):438-443. PubMed ID: 33690265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.
    Chatterjee D; Tauzin A; Laumaea A; Gong SY; Bo Y; Guilbault A; Goyette G; Bourassa C; Gendron-Lepage G; Medjahed H; Richard J; Moreira S; Côté M; Finzi A
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.
    Cheng L; Song S; Zhou B; Ge X; Yu J; Zhang M; Ju B; Zhang Z
    Virol J; 2021 Apr; 18(1):87. PubMed ID: 33910569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
    Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H
    Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.